The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Hepatotoxicity of statins and other lipid‐lowering agents
Abstract
Statins are generally well tolerated and adverse effects are relatively rare. Clinical trials are underpowered to detect uncommon adverse effects such as idiosyncratic drug‐induced liver injury. This review is aimed at covering the current knowledge on the hepatotoxicity associated with statins and other lipid lowering drugs. Both atorvastatin and simvastatin have been associated with more than 50 case reports of liver injury and other statins have been implicated in this type of liver injury as well. Idiosyncratic liver injury due to statins has been reported to occur 1.9%‐5.5% of patients in prospective series of drug‐induced liver injury. Atorvastatin and simvastatin have been associated with positive rechallenge and some case reports have described liver injury following dose escalation of the implicated statin. Mortality from liver injury and/or liver transplantation has been documented in a few patients with statin induced liver injury although the vast majority of patients with liver injury have recovered after cessation of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Statins raised concerns of statin-induced hepatotoxicity.
“and raised concerns of statin-induced hepatotoxicity.95”
From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Flagged first, then by citations
Research works printed but not linked: 47
- 10.1016/S0140-6736(94)91755-8 · DOI
- Bradford RH, 1999, Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia, Arch Intern Med, 151, 43, 10.1001/archinte.1991.00400010067008 · DOI
- 10.1001/jama.285.13.1711 · DOI · Paper page
- 10.1007/s40264-014-0182-7 · DOI
- Feydy P, 1991, A case of hepatitis caused by simvastatin [French], Gastroenterol Clin Biol, 15, 94
- Ballare M, 1991, Acute cholestatic hepatitis during simvastatin administration, Recenti Prog Med, 82, 233
- 10.5694/j.1326-5377.1991.tb116406.x · DOI
- 10.1002/hep.20800 · DOI · Paper page
- 10.1016/j.gastro.2005.05.006 · DOI · Paper page
- 10.1053/j.gastro.2008.09.011 · DOI · Paper page
- 10.1038/ajg.2010.287 · DOI · Paper page
- 10.1097/MCG.0b013e3181c5e9cc · DOI
- 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- 10.1055/s-0029-1240010 · DOI
- 10.1016/j.jhep.2011.07.023 · DOI
- Perdices EV, 2014, Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry, Rev Esp Enferm Dig, 106, 246
- 10.1002/hep.27157 · DOI
- 10.1053/j.gastro.2004.02.015 · DOI · Paper page
- 10.1002/hep.21848 · DOI · Paper page
- 10.1007/s10620-011-1950-1 · DOI
- 10.1016/j.amjmed.2005.02.008 · DOI
- 10.1002/lt.20204 · DOI · Paper page
- 10.1016/j.jhep.2014.11.019 · DOI
- 10.1002/hep.22272 · DOI
- 10.1002/hep.26208 · DOI · Paper page
- 10.1002/hep.23317 · DOI
- 10.1016/S0002-9343(02)01178-6 · DOI
- 10.5694/j.1326-5377.2002.tb04559.x · DOI
- 10.1002/hep.23588 · DOI · Paper page
- 10.1016/j.cgh.2014.07.062 · DOI · Paper page
- 10.1001/archinte.159.15.1811-a · DOI
- 10.1097/00042737-200308000-00014 · DOI
- Heyningen C, 2005, Drug‐induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe, Curr Opin Lipidol, 16, 597
- 10.1097/00004836-200609000-00018 · DOI
- 10.1016/j.jhep.2010.12.041 · DOI · Paper page
- 10.1016/j.jhep.2016.05.003 · DOI · Paper page
- 10.1002/hep.28323 · DOI · Paper page
- 10.1016/S0168-8278(03)00464-1 · DOI
- 10.1016/j.dld.2006.04.013 · DOI
- 10.1001/jama.1959.63010170008010c · DOI
- 10.1097/00007611-198302000-00023 · DOI
- 10.1001/jama.1974.03230270046027 · DOI
- Rourk RM, 1998, Niacin. Help for your cholesterol–harm for your liver, N C Med J, 59, 87
- 10.1046/j.1365-2796.2001.00848.x · DOI
- Bustamante Balén M, 1998, Acute hepatitis caused by gemfibrozil, Gastroenterol Hepatol, 21, 419
- 10.1056/NEJM197808102990622 · DOI
- 10.1002/hep.21424 · DOI · Paper page
Cited by
Sorted by citations
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01202-1 · Cited by 38
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
An overview on nanoplatforms for statins delivery: Perspectives for safe and effective therapy
Etemad, L., Salmasi, Z., Moosavian Kalat, S. A., Moshiri, M., Zamanian, J., Kesharwani, P., & Sahebkar, A. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116572 · Cited by 18
Metadata
- Authors
- Björnsson, E. S.
- Affiliations
- Faculty of Medicine The National University Hospital of Iceland Reykjavik Iceland
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2016-11-27
- Volume
- 37
- Issue
- 2
- Pages
- 173-178
- ISSN
- 1478-3223
- 1478-3231
- Cited by
- 173
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
